"The success of Prevnar in battling so-called pneumococcal infections since its launch in 2000 has stemmed not only from the direct protection provided to individuals, but also in building up "herd immunity," in which unvaccinated or partially vaccinated people get protection because the targeted bugs don't circulate as widely as before the vaccine was introduced."